BioSpace News Archive

Economic activity in the services sector grew in December for the seventh month in a row, say the nation’s purchasing and supply executives in the latest Services ISM® Report On Business®.

Tidepool, a 5013 nonprofit, announced completion of its FDA submission of Tidepool Loop, an automated insulin dosing app intended for the management of type 1 diabetes.

Repertoire Immune Medicines, a clinical-stage biotech company creating a new category of immune therapies for cancer, autoimmunity and infectious disease, today announced that John Cox, Chief Executive Officer, will participate in the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 8:05 a.m. EST

Evotec SE announced that its management will be presenting at and attending the following upcoming conferences in the first quarter of 2021:

Pharmacy Times®, the leading multimedia resource for pharmacy professionals, adds the Association of Community Cancer Centers to its Strategic Alliance Partnership program.

Mileutis Ltd. (“Mileutis”), an Israeli biopharmaceutical company which helps mitigate the use of antibiotics in animals through its safe and residue-free immunomodulator peptides, today announced that its CEO, David Javier Iscovich is set to present a corporate presentation at the 39th Annual J.P. Morgan Healthcare Conference.

First Dedicated Device to Enable Coronary Access and Prevent Coronary Obstruction During Transcatheter Aortic Valve Replacement

Oakville, Ontario--(Newsfile Corp. - January 7, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (“Cardiol” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies for inflammatory heart disease, announced today that David Elsley, President and CEO of Cardiol, will participate in the following upcoming virtual investor conferences:

REMD Biotherapeutics, Inc. (“REMD Bio”), together with its subsidiary, Beijing CoSci-REMD Bio Med-Tech Co, Ltd (“Cosci-REMD Bio”), today announced they have completed enrollment and have top-line results in a phase 2 study of volagidemab (REMD-477) in patients with type 1 diabetes. The study , which enrolled approximately 150 patients at eleven clinical sites in the United States, is a randomized, placebo-controlled, d

ExCellThera Inc., a clinical-stage molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today the publication of new data describing the mechanism of action of UM171, the proprietary molecule which forms the basis of ECT-001 Cell Therapy.